MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
Merit Medical Systems Financial Ratios 2011-2026 | MMSI
Annual Financial Ratios Merit Medical Systems
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
49.4 | 48.5 | 53.5 | 64.3 | -305.0 | 374.0 | 68.0 | 82.9 | 54.5 | 30.6 | 28.8 | 37.6 | 29.5 | 23.9 |
P/S |
4.4 | 3.6 | 3.5 | 2.9 | 3.1 | 2.0 | 3.2 | 3.1 | 1.8 | 1.3 | 1.3 | 1.4 | 1.5 | 1.5 |
EPS |
2.1 | 1.6 | 1.3 | 0.9 | -0.2 | 0.1 | 0.8 | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 0.6 |
EV (Enterprise Value) |
6.6 B | 5.11 B | 4.45 B | 3.65 B | 3.65 B | 2.8 B | 3.48 B | 2.68 B | 1.52 B | 1.04 B | 966 M | 938 M | 895 M | 631 M |
EBITDA per Share |
4.44 | 3.71 | 2.98 | 2.58 | 1.67 | 2.61 | 2.46 | 2.03 | 1.78 | 1.73 | 1.78 | 1.51 | 1.3 | 1.49 |
EV/EBITDA |
25.0 | 21.6 | 16.9 | 24.7 | 25.5 | 17.7 | 12.3 | 11.5 | 13.4 | 14.8 | 9.8 | |||
PEG |
3.16 | 3.76 | 4.38 | 5.38 | -181.57 | -4.27 | 1.59 | 3.51 | -3.39 | 21.76 | 0.78 | -2.18 | -1.45 | 0.35 |
P/B |
4.3 | 3.8 | 3.5 | 3.0 | 3.1 | 2.1 | 3.1 | 3.4 | 2.2 | 1.6 | 1.5 | 1.5 | 1.5 | 1.5 |
P/CF |
26.9 | 31.5 | 34.9 | 21.1 | 18.2 | -553.4 | 141.6 | 106.0 | 59.1 | 44.1 | 37.9 | -63.9 | -30.3 | -20.2 |
ROE % |
8.73 | 7.85 | 6.51 | 4.66 | -1.03 | 0.57 | 4.50 | 4.07 | 4.04 | 5.11 | 5.28 | 4.08 | 5.17 | 6.45 |
ROA % |
4.98 | 4.06 | 4.48 | 2.94 | -0.59 | 0.31 | 2.59 | 2.48 | 2.13 | 3.06 | 3.07 | 2.28 | 2.79 | 5.16 |
ROCE % |
11.29 | 10.31 | 7.65 | 5.86 | -0.16 | 2.51 | 4.10 | 4.59 | 4.14 | 5.59 | 6.06 | 4.80 | 5.08 | 9.68 |
Current Ratio |
2.3 | 2.1 | 3.2 | 2.7 | 2.4 | 2.5 | 2.5 | 2.7 | 2.8 | 2.3 | 2.5 | 2.5 | 2.2 | 3.1 |
DSO |
49.5 | 49.7 | 50.3 | 50.8 | 57.2 | 61.8 | 62.0 | 58.3 | 52.3 | 52.7 | 57.7 | 52.1 | 53.1 | 45.9 |
DIO |
156.1 | 154.4 | 140.9 | 130.0 | 137.4 | 146.5 | 147.8 | 141.1 | 130.0 | 126.3 | 117.8 | 118.1 | 145.5 | 131.5 |
DPO |
34.4 | 36.4 | 35.9 | 32.7 | 33.9 | 35.4 | 40.4 | 31.7 | 33.0 | 45.2 | 38.2 | 38.0 | 59.6 | 42.8 |
Operating Cycle |
205.6 | 204.1 | 191.2 | 180.8 | 194.6 | 208.3 | 209.8 | 199.4 | 182.4 | 178.9 | 175.4 | 170.2 | 198.5 | 177.5 |
Cash Conversion Cycle |
171.2 | 167.7 | 155.3 | 148.1 | 160.7 | 172.8 | 169.4 | 167.6 | 149.4 | 133.7 | 137.2 | 132.2 | 139.0 | 134.7 |
All numbers in USD currency
Quarterly Financial Ratios Merit Medical Systems
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.55 | 0.51 | - | 0.49 | 0.61 | 0.49 | - | 0.45 | 0.35 | 0.36 | - | 0.27 | 0.27 | 0.19 | - | 0.21 | 0.09 | 0.2 | 0.28 | -0.05 | -0.34 | -0.06 | -0.08 | -0.06 | 0.12 | 0.11 | 0.17 | 0.31 | 0.22 | 0.1 | 0.14 | -0.07 | 0.19 | 0.33 | 0.17 | 0.02 | 0.16 | 0.1 | 0.14 | 0.11 | 0.17 | 0.12 | 0.2 | 0.18 | 0.09 | 0.07 | 0.15 | 0.13 | 0.09 | 0.02 | 0.02 | 0.17 | 0.14 | 0.14 | 0.12 | 0.11 | 0.19 | 0.19 |
EBITDA per Share |
1.32 | 1.19 | - | 0.93 | 1.2 | 1.03 | - | 0.88 | 0.73 | 0.82 | - | 0.54 | 0.62 | 0.63 | - | 1.4 | 0.38 | 0.64 | 0.29 | 1.27 | 0.51 | 0.45 | -0.06 | 1.19 | 1.04 | 0.58 | 0.25 | 1.34 | 0.95 | 0.48 | 0.26 | 0.8 | 0.78 | 0.41 | 0.28 | 0.78 | 0.71 | 0.39 | - | 0.82 | 0.69 | 0.41 | - | 0.9 | 0.58 | 0.35 | - | 0.76 | 0.53 | 0.22 | - | 0.61 | 0.44 | 0.3 | - | 0.5 | 0.55 | 0.42 |
ROE % |
8.60 | 9.19 | 7.21 | 9.31 | 9.26 | 8.16 | 5.55 | 6.95 | 6.25 | 6.00 | 3.83 | 5.01 | 4.79 | 3.86 | 2.80 | 4.40 | 2.91 | 0.42 | -1.03 | -3.07 | -3.12 | -0.41 | 0.57 | 2.00 | 4.14 | 4.59 | 4.50 | 4.53 | 2.22 | 2.45 | 4.07 | 4.57 | 5.29 | 5.35 | 4.04 | 3.91 | 4.75 | 4.87 | 5.11 | 5.72 | 6.52 | 5.79 | 5.32 | 4.94 | 4.50 | 4.57 | 4.08 | 2.64 | 3.15 | 3.82 | 5.17 | 6.39 | 5.77 | 6.10 | 6.45 | 1.28 | 1.92 | 1.86 |
ROA % |
4.87 | 5.12 | 3.92 | 5.34 | 5.58 | 5.17 | 3.76 | 4.69 | 4.20 | 3.75 | 2.23 | 2.96 | 2.10 | 2.40 | 1.69 | 2.61 | 1.71 | 0.26 | -0.59 | -1.75 | -1.77 | -0.23 | 0.31 | 1.12 | 2.34 | 2.62 | 2.59 | 2.64 | 1.29 | 1.47 | 2.48 | 2.66 | 3.08 | 3.00 | 2.13 | 2.16 | 2.68 | 2.85 | 3.06 | 3.39 | 3.81 | 3.36 | 3.07 | 2.81 | 2.54 | 2.56 | 2.28 | 1.47 | 1.72 | 2.07 | 2.79 | 3.82 | 3.81 | 4.48 | 5.16 | 1.02 | 1.54 | 1.49 |
ROCE % |
11.65 | 12.09 | 9.29 | 12.15 | 12.19 | 11.00 | 7.50 | 9.22 | 8.07 | 7.85 | 5.32 | 6.89 | 6.75 | 5.48 | 3.92 | 5.59 | 4.03 | 1.15 | -0.16 | -2.19 | -2.50 | 0.76 | 1.62 | 3.45 | 6.01 | 6.35 | 6.28 | 6.77 | 4.65 | 5.00 | 4.89 | 5.46 | 5.93 | 6.28 | 7.00 | 6.30 | 7.54 | 7.84 | 6.33 | 9.17 | 10.19 | 9.26 | 6.03 | 8.10 | 7.32 | 7.30 | 4.17 | 6.55 | 6.86 | 7.35 | 6.63 | 8.46 | 7.90 | 8.78 | 7.72 | 1.82 | 3.04 | 2.86 |
Current Ratio |
2.4 | 2.4 | 2.3 | 2.2 | 2.2 | 2.1 | 2.1 | 3.1 | 2.9 | 3.3 | 3.2 | 3.0 | - | 2.8 | 2.7 | 2.6 | 2.5 | 2.5 | 2.4 | 2.4 | 2.4 | 2.4 | 2.2 | 2.2 | 2.2 | 2.2 | 2.4 | 2.4 | 2.4 | 2.4 | 2.5 | 2.5 | 2.5 | 2.5 | 2.1 | 2.1 | 2.1 | 2.1 | 2.5 | 2.5 | 2.5 | 2.5 | 2.4 | 2.4 | 2.4 | 2.4 | 2.3 | 2.3 | 2.3 | 2.3 | 2.2 | 2.2 | 2.2 | 2.2 | 5.0 | 5.0 | 5.0 | 5.0 |
DSO |
48.2 | 50.0 | - | 50.0 | 49.0 | 50.6 | - | 49.0 | 48.6 | 51.3 | - | 24.8 | 24.1 | 51.0 | - | 52.0 | 49.4 | 54.4 | 51.9 | 54.9 | 61.3 | 56.6 | 55.0 | 58.3 | 55.5 | 56.0 | 53.7 | 56.5 | 55.7 | 54.5 | 50.5 | 53.7 | 51.6 | 49.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.6 | 40.9 | 40.5 | - |
DIO |
147.8 | 155.3 | - | 152.3 | 155.0 | 161.1 | - | 160.8 | 162.4 | 159.2 | - | 71.0 | 66.0 | 133.9 | - | 125.4 | 115.3 | 132.6 | - | 127.3 | 134.7 | 138.3 | - | 148.3 | 143.4 | 144.4 | - | 150.7 | 144.4 | 140.0 | - | 143.4 | 138.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
30.6 | 32.9 | - | 29.1 | 26.8 | 30.4 | - | 29.2 | 34.7 | 38.4 | - | 18.2 | 16.6 | 33.6 | - | 32.7 | 31.2 | 34.2 | - | 32.0 | 33.9 | 34.1 | - | 35.9 | 34.7 | 37.1 | - | 41.2 | 39.5 | 35.3 | - | 32.2 | 31.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
195.9 | 205.3 | - | 202.3 | 204.0 | 211.7 | - | 209.8 | 211.1 | 210.6 | - | 95.7 | 90.2 | 184.9 | - | 177.3 | 164.8 | 187.1 | 51.9 | 182.1 | 196.0 | 194.9 | 55.0 | 206.6 | 198.9 | 200.4 | 53.7 | 207.2 | 200.1 | 194.5 | 50.5 | 197.1 | 190.0 | 49.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.6 | 40.9 | 40.5 | - |
Cash Conversion Cycle |
165.3 | 172.4 | - | 173.2 | 177.2 | 181.3 | - | 180.7 | 176.3 | 172.1 | - | 77.5 | 73.6 | 151.3 | - | 144.7 | 133.6 | 152.8 | 51.9 | 150.1 | 162.1 | 160.8 | 55.0 | 170.7 | 164.2 | 163.3 | 53.7 | 165.9 | 160.6 | 159.2 | 50.5 | 164.8 | 158.9 | 49.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.6 | 40.9 | 40.5 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Merit Medical Systems, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 184.86 | 1.31 % | $ 53.2 B | USA |
 |
Baxter International
BAX
|
$ 21.74 | 1.85 % | $ 11.2 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.29 | -8.21 % | $ 228 M | USA |
 |
ICU Medical
ICUI
|
$ 155.85 | 4.08 % | $ 3.84 B | USA |
 |
Alcon
ALC
|
$ 82.21 | -1.21 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
$ 32.79 | 1.27 % | $ 1.57 B | USA |
 |
electroCore
ECOR
|
$ 6.16 | -0.16 % | $ 34 K | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.58 | -0.56 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 92.55 | 0.75 % | $ 2.08 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.22 | 0.13 % | $ 458 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 7.9 | - | $ 163 M | USA |
 |
The Cooper Companies
COO
|
$ 84.11 | 0.51 % | $ 16.7 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 61.61 | 1.55 % | $ 3.1 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 150.56 | -5.24 % | $ 4.82 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 119.69 | 2.21 % | $ 5.8 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.72 | 0.64 % | $ 215 M | USA |
 |
OraSure Technologies
OSUR
|
$ 2.76 | -2.47 % | $ 205 M | USA |
 |
Masimo Corporation
MASI
|
$ 175.38 | 0.03 % | $ 9.35 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 504.2 | 0.93 % | $ 180 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.07 | -3.95 % | $ 21.1 M |  Israel |
 |
Nephros
NEPH
|
$ 4.14 | 6.43 % | $ 43 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.26 | -2.04 % | $ 20.7 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.63 | 0.88 % | $ 2.57 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 29.16 | 1.53 % | $ 4.9 B | USA |
 |
Pro-Dex
PDEX
|
$ 39.55 | 1.41 % | $ 130 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.98 | -12.38 % | $ 1.48 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Stereotaxis
STXS
|
$ 2.08 | -0.24 % | $ 168 M | USA |
 |
Repligen Corporation
RGEN
|
$ 136.76 | -0.34 % | $ 7.62 M | USA |
 |
ResMed
RMD
|
$ 258.04 | 0.68 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
$ 23.17 | -0.26 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
$ 250.32 | -0.34 % | $ 24.7 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.67 | -3.48 % | $ 20.1 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 17.65 | -1.29 % | $ 867 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 115.88 | 3.65 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
$ 67.96 | 2.09 % | $ 247 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 241.54 | -0.94 % | $ 17.5 B | USA |